Web Results

caselaw.findlaw.com/us-3rd-circuit/1313639.html

Mar 11, 2005 ... Alvin “Rob” Emory brought suit against his longtime employer, AstraZeneca Pharmaceuticals LP (“AstraZeneca”), alleging disability discrimination in the form ... to promote and failure to provide reasonable accommodations in violation of the Americans with Disabilities Act (“ADA”), 42 U.S.C. § 12101 et seq.

caselaw.findlaw.com/us-3rd-circuit/1681038.html

Oct 20, 2014 ... ASTRAZENECA PHARMACEUTICALS L.P.; Astrazeneca LP; Bristol–Myers Squibb Company; E.I. DuPont De Nemours & Company; DuPont ... Plaintiff Karl S . Schumann, proceeding as a qui tam relator under the False Claims Act (FCA), 31 U.S.C. § 3729 et seq., and corresponding state laws, appeals the ...

www.reuters.com/article/us-astrazeneca-crestor-idUSKCN0ZZ2VW

Jul 19, 2016 ... Moss's decision on Tuesday is in line with a ruling last year by another judge in the same court, who allowed generic versions of Otsuka's antipsychotic drug Abilify to go on the market even though the drug had recently been approved for a rare disease. The case is AstraZeneca Pharmaceuticals LP et al v.

www.law360.com/articles/887798/astrazeneca-prevails-in-trial-over-diabetes-drug-patent

Feb 3, 2017 ... A Delaware federal judge ruled Thursday that AstraZeneca's patents covering its $3.5 billion diabetes drugs Onglyza and Kombiglyze XR were not invalid for ... The case is AstraZeneca AB v. Aurobindo Pharma Ltd. et al., case number 1:14- cv-00664, in the U.S. District Court for the District of Delaware.

jamanetwork.com/journals/jama/fullarticle/2088852

Jan 6, 2015 ... Abridged Period Life Table for Men and Women With Type 1 Diabetes vs General Population Without Type 1 Diabetes in Scotland 2008-2010. Table 2. ... Livingstone SJ, Looker HC, Hothersall EJ, et al. Risk of ..... Data analysis was carried out using Stata version 11.0 (StataCorp LP) and R version 3.0.1.

law.justia.com/cases/federal/district-courts/new-jersey/njdce/2015

TEAMSTERS HEALTH AND WELFARE FUND OF PHILADELPHIA AND VICINITY et al v. COURIER-POST ... Docket Number: 2:2015cv01761. GUILLEN et al v. SIX FLAGS GREAT ADVENTURE LLC. et al. Date: December 29, 2015. Docket Number: 2:2014cv02091 ..... NOVARTIS PHARMACEUTICALS CORPORATION

law.justia.com/cases/federal/district-courts/new-jersey/njdce/2011

Docket Number: 3:2011cv03408. STEWART v. CAMDEN COUNTY CORRECTIONAL FACILITY et al. Date: December 12, 2011. Docket Number: 1: 2010cv06428. -TJB POZNANOVICH v. ASTRAZENECA PHARMACEUTICALS LP et al. Date: December 12, 2011. Docket Number: 3:2011cv04001. STEWART v. TAYLOR et al

onlinelibrary.wiley.com/doi/10.1111/dme.13256/pdf

Aug 31, 2016 ... Mean weight change was +0.5 kg with IDegLira vs –1.0 kg with placebo [ estimated treatment difference 1.48 kg (95% CI 0.90; 2.06);. P < 0.001]. Confirmed .... IDegLira in combination with sulphonylureas H. W. Rodbard et al. ..... by Sanofi, Merck, AstraZeneca Pharmaceuticals LP, Janssen,. Eli Lilly and Co ., ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC4426486

IMPORTANCE. Type 1 diabetes has historically been associated with a significant reduction in life expectancy. Major advances in treatment of type 1 diabetes have occurred in the past 3 decades. Contemporary estimates of the effect of type 1 diabetes on life expectancy are needed.